Ed Yardeni Downplays Recession Fears But Warns, 'We Need More Bears To Keep The Bull Market Going' - SPDR S&P 500 (ARCA:SPY)

Category: Finance

Veteran Wall Street investor Ed Yardeni downplays recession risk but notes disappearance of bearish sentiment as a contrarian signal for bull market sustainability. Yardeni emphasizes impact of weak economic data on stock prices, potential Fed rate cuts, and inflationary policies post-election. He refrains from revising S&P 500 targets despite surpassing year-end goal and reconsiders future projections. Yardeni highlights missed opportunities by bearish investors, changes in investment strategists, and the need for more bears to sustain the bull market.

Keywords: Ed Yardeni, recession risk, stock market, Federal Reserve, interest rates, inflation, S&P 500, investment strategies, bearish sentiment, bull market

Source: Benzinga

Update At: 7/16/2024

Related Sources

Pfizer stock gains after raising annual earnings outlook (NYSE:PFE)

Pfizer's shares rose 4.1% after the company exceeded Q2 earnings expectations and raised its full-year outlook, driven by its oncology portfolio and cost realignment efforts. Adjusted earnings were $0.60 per share on $13.28B revenue, marking the first year-over-year revenue growth since Q4 2022. Despite declines in COVID-19 product revenues, overall operational revenue grew 3%. The company raised its 2024 revenue guidance by $1B, anticipating 9-11% growth excluding COVID products.

Seeking Alpha

Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Pfizer (NYSE:PFE)

Pfizer Inc. is set to announce its Q2 financial results, with expected earnings of 46 cents per share and revenue of $13.02 billion. The company received European Commission approval for DURVEQTIX, a gene therapy for hemophilia B. Recent analyst ratings show mixed sentiments, with price targets ranging from $29 to $45.

Benzinga

Merck & Co., Inc.'s (NYSE:MRK) Dismal Stock Performance Reflects Weak Fundamentals

Merck's stock has declined 3.7% over the past three months, with a return on equity (ROE) of 5.7%, significantly below the industry average of 22%. The company's earnings have been shrinking, and its high payout ratio of 110% indicates it is depleting resources to maintain dividend payments. Analysts expect an improvement in ROE to 39% as the payout ratio drops to 32% over the next three years, but caution is advised due to the current unsatisfactory performance.

Yahoo Finance

Is An Earnings Beat In The Cards For Merck Stock?

Merck is set to report Q2 2024 results on July 30, expecting revenue of $15.9 billion and adjusted earnings of $2.20, driven by strong sales of Keytruda and Gardasil. Despite recent stock gains, MRK has underperformed the S&P 500 in 2021 and 2023. The company faces challenges from generic competition but remains optimistic about growth in Keytruda and Gardasil, particularly in China. Valuation estimates suggest MRK is appropriately priced at $135 per share.

Forbes

Is Procter & Gamble (PG) a Smart Investment Pre-Q4 Earnings?

Procter & Gamble is expected to report fourth-quarter fiscal 2024 results on July 30, with projected revenues of $20.7 billion, reflecting a 0.9% increase year-over-year. The company has shown consistent earnings growth, with a trailing four-quarter earnings surprise of 6.5%. Despite challenges such as supply chain issues and geopolitical tensions, P&G's strong brand portfolio and pricing strategies are anticipated to drive organic sales growth. However, currency fluctuations and rising costs may impact profitability.

Yahoo Finance

Procter & Gamble falls after organic sales miss expectations (NYSE:PG)

Procter & Gamble reported mixed FQ4 earnings with organic sales rising 2%, missing the 3.4% estimate. The Health Care segment saw a 4% increase, while Baby, Feminine, and Family Care segment sales declined by 1%. The company expects FY25 revenue growth of 2% to 4% and EPS between $6.91 and $7.05. Shares fell 2.68% in premarket trading.

Seeking Alpha

Microsoft or AMD: Deutsche Bank Chooses the Superior Tech Stock to Buy Ahead of Earnings - TipRanks.com

Microsoft is favored over AMD as the superior tech stock ahead of earnings, driven by strong AI integration and solid financial performance. Analysts expect Microsoft to report significant revenue growth, while AMD shows modest growth but faces caution due to cyclical weaknesses in non-AI sectors.

Tipranks

US OPEN: Russell 2000 leads gains on Wall Street 📈

Wall Street shows positive momentum with the Russell 2000 index up 1.65%, driven by better-than-expected retail sales and Bank of America's earnings. Bank of America reports net interest income of $14.5 billion, while Match shares rise 7% due to activist investor interest. Morgan Stanley's Q2 earnings exceed expectations but shares open lower, and United Health Group sees a 3.1% increase despite raising earnings estimates due to cybersecurity issues. Analysts adjust target prices for Goldman Sachs, Macy's, and Netflix based on recent performance.

XTB.com

Major indices are higher in early US trade. AMD, MIcrosoft, Starbucks and Pinterest report | Forexlive

Major US indices are up in early trading, with the Dow up 159.13 points, S&P up 24.31 points, and NASDAQ up 86.05 points. The small-cap Russell 2000 also shows gains. Crude oil prices have dropped, while gold has increased. Bitcoin fluctuates around $66,486 after trading above $70,000 yesterday.

Forexlive

Can AMD Stock Rebound to $200? Here’s What Christopher Rolland Expects - TipRanks.com

AMD shares have fallen 27% in the last 4 months despite an increase in 2024 revenue guidance for the MI300 accelerator. Analyst Christopher Rolland predicts further revenue increases, estimating MI300 sales could reach $5 billion in 2024. However, concerns about order cancellations from major clients and competition from Nvidia's GB200 platform pose risks. Rolland rates AMD shares as a Buy with a $200 price target, while the consensus among analysts is a Strong Buy with a 39.5% expected appreciation over the next 12 months.

Tipranks